Comparative Pharmacology
Head-to-head clinical analysis: IODIXANOL versus ISOPAQUE 280.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODIXANOL versus ISOPAQUE 280.
IODIXANOL vs ISOPAQUE 280
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodixanol is a nonionic, iso-osmolar iodinated contrast agent that attenuates X-rays, allowing visualization of vascular structures and organ parenchyma. It does not bind to or interact with specific receptors.
Isopaque 280 (metrizoate) is an ionic, high-osmolar iodinated radiocontrast agent that attenuates X-rays by increasing the density of tissues where it distributes, thereby enhancing vascular and organ visualization during imaging.
Intravenous injection of 270-350 mg iodine/kg (0.5-1.0 mL/kg of 270 mg I/mL solution) for CT; 300-400 mg iodine/kg for angiography. Administer as bolus or infusion per procedure.
Iohexol (ISOPAQUE 280) is administered intravenously, intra-arterially, or by other appropriate routes. Typical adult dose for CT imaging: 50–150 mL (concentration 280 mg I/mL) as a bolus or infusion. For angiography: 5–80 mL per injection, depending on procedure. Repeat doses may be given up to a total of 350 mL.
None Documented
None Documented
Clinical Note
moderateIodixanol + Metformin
"The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin."
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 10-12 hours, requiring dose adjustment and monitoring.
Terminal elimination half-life is 1.5–2 hours in patients with normal renal function; prolonged to >10 hours in severe renal impairment, requiring dose adjustment.
Primarily renal: approximately 97% of the administered dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Less than 3% is excreted in feces via biliary elimination.
Renal: approximately 95% of the dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Fecal: <5%; biliary excretion is negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent